key: cord-0862463-nb8sqlz0 authors: Thaler, Johannes; Ay, Cihan; Knoebl, Paul title: The path of uncovering a prothrombotic thrombocytopenic syndrome after viral vector‐based COVID‐19 vaccination: Where there is much light, the shadow is deep date: 2021-11-02 journal: Res Pract Thromb Haemost DOI: 10.1002/rth2.12609 sha: 0a9cedc927e4b1b2d404d1e8b1fe95c98488c613 doc_id: 862463 cord_uid: nb8sqlz0 nan "Where there is much light, the shadow is deep." 1 These famous words from a play by Johann Wolfgang von Goethe, a great poet and multitalented individual in the 18th century, are true beyond the obvious field of physics. Also, in modern medicine, light and shadow often coexist. In March 2021, only a few weeks after the first cases of unusual thromboses associated with ChAdOx1 nCov-19 vaccination were observed, Greinacher et al 2 published a preprint article that characterized this syndrome and suggested a treatment strategy, which later turned out to be highly effective. Pointedly, they referred to this as a prothrombotic syndrome that clinically resembles heparin-induced thrombocytopenia (HIT; but without exposure to heparin) and coined the term vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). During the following weeks and months, further clinical and experimental data were published at an impressive pace, setting the ground for evidence-based effective treatment. [3] [4] [5] [6] [7] [8] In this journal, clinical and laboratory signs of vaccine-induced prothrombotic thrombocytopenia but without thrombosis, guidance does not suggest treatment in these cases. We published a case report indicating that thrombosis can be prevented in these patients upon rapid initiation of treatment, very much like the case in patients with HIT. 5 Recently, we also published a case series supporting our view that upon swift initiation of treatment, thrombosis can be prevented in these patients. 17 We pre-VITT is very confusing because it (in addition to available guidance) suggests that rapid initiation of a lifesaving treatment may not be warranted in patients without thrombosis, as they only have a "pre"syndrome. This is obviously wrong and can be very easily misinterpreted by the majority of physicians who are not coagulation experts. We maintain that patients with VIPIT without thrombosis should be treated similarly to those with thrombosis. The term VIPIT is more encompassing and may be preferred to other nomenclature. More research on intervention in the absence of thrombosis is needed to bring knowledge from the Shadow into the Light. PK and JT declare no conflicts of interest. CA declares that he https://orcid.org/0000-0002-9613-8658 Cihan Ay https://orcid.org/0000-0003-2607-9717 Cihan Ay @Cihan_Ay_MD Götz von Berlichingen with the Iron Hand A prothrombotic thrombocytopenic disorder resembling heparininduced thrombocytopenia following coronavirus-19 vaccination Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination Prothrombotic immune thrombocytopenia after COVID-19 vaccination Successful treatment of vaccineinduced prothrombotic immune thrombocytopenia (VIPIT) Thrombotic thrombocytopenia after Ad26.COV2.S vaccination Therapeutic plasma exchange in vaccine-induced immune thrombotic thrombocytopenia PF4 immunoassays in vaccineinduced thrombotic thrombocytopenia An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2 Heparin-induced thrombocytopenia Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination Thrombotic risk in COVID-19: a case series and case-control study Proposed Brighton Collaboration Process for Developing a Standard Case Definition for Study of New Clinical Syndrome X, as Applied to Thrombosis With Thrombocytopenia Syndrome (TTS) The ISTH Releases Interim Guidance on Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia Vaccine-induced thrombocytopenia with severe headache The path of uncovering a prothrombotic thrombocytopenic syndrome after viral vector-based COVID-19 vaccination: Where there is much light, the shadow is deep